Cytotoxic in Medical Technology
Navigation Links
Cytotoxic in Medical Technology
... Effectiveness Of New Highly-Potent And cytotoxic (HP/C) Facility Through Airborne Particulate ... and manufacturing of highly-potent and cytotoxic compounds.
"The testing results of our HP/C ... services to include highly potent and cytotoxic compounds, and do it in the safest possible way," ...
... a disease-specific antigen can induce both cytotoxic T-cell and antibody (B-cell) immune responses against that antigen. cytotoxic T-cells, also referred to as CD8 T-cells, are ... near future; Poly-ICR's ability to induce both cytotoxic and antibody immune responses; and our ...
... first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to ... of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product ... the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. ...
... may relate to the high anti-tumor activity of cytotoxic T cells recruited by blinatumomab," commented ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ... class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer ...
... can be delivered subcutaneously, and show that cytotoxic T cell activity is not impaired by long-term BiTE ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ... class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful ...
... of a physician qualified in the use of cytotoxic anti-cancer therapy. Malignant pleural ... is given in combination with other cytotoxic agents; most of these patients had pre-existing ... (Usually when given in combination with other cytotoxic agents and with pre-existing cardiovascular ...
... convenience." About temozolomide TEMODAL (temozolomide), a cytotoxic agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. cytotoxic agents are designed to impact the replication of cells that divide ...
... autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-EpCAM antibody adecatumumab (MT201) against KRAS-mutated ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer ... from unresectable malignant mesothelioma. "The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's ...
... greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 ... do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent which should not be given to healthy volunteers, this evaluation is ...
... second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...
... (3) Natale, R. et al. Vandetanib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). ABS 31610. ASCO. 2009. (4) Ferlay, J. et al. GLOBOCAN 2002: Cancer Incidence, ...
... Presenter: Elena G. Chiorean, MD Location: Level 2 - West Hall C. Poster Session Track: #79 Developmental Therapeutics: cytotoxic Chemotherapy; Poster Board B19 (Abstract # 2558) About SF1126 SF1126 is the only clinical stage vascular targeted ...
... cell lung cancers (SCLC). In in vitro preclinical studies, a fully human, non-fucosylated anti-fucosyl-GM1 antibody, MDX-1110, demonstrated robust cytotoxic effector function (both antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity) for killing tumor cells. Additionally, ...
... EP-100 was fast-acting, destroying LHRH receptor over-expressing OVCAR-3 cells within an hour compared to the unconjugated CLIP 71 which was less cytotoxic and was slow-acting (p<0.005). LHRH receptor negative SKOV-3 cells were significantly less sensitive to EP-100 than OVCAR-3 cells and the effects ...
... the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other ...
... been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), ...
... The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies. The Principle Investigator of the trial is Dr. Charles Shapiro, Director of Breast Oncology at Ohio State University. The trial ...
... mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the ...
... trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in ...
... multi-center, open label, stratified study of RAD001 in 160 patients with advanced pancreatic NET, who became resistant to prior treatment with cytotoxic chemotherapy. In the monotherapy treatment group, 115 patients received RAD001 alone. In the combination treatment group, 45 patients whose tumors ...
... properties of corticosteroid medications such as prednisone and methylprednisolone often improve symptoms within days. Immune-suppressing and cytotoxic drugs are used when vasculitis is severe and does not respond to corticosteroids. Thanks to drug treatments, some types of vasculitis that were ...
... synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...
... with CUP pose a therapeutic dilemma and treatment is often empiric with a "trial and error" approach. In the era of rapidly growing effective cytotoxic and targeted therapies for known cancers, quicker and more accurate methods of identifying the tissue of origin of CUP cases would permit the use of ...
... a disease-specific antigen can induce both cytotoxic T-cell and antibody (B-cell) immune responses against that antigen. cytotoxic T-cells, also referred to as CD8 T-cells, are ... near future; Poly-ICR's ability to induce both cytotoxic and antibody immune responses; and our ...
... first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to ... of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product ... the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. ...
... may relate to the high anti-tumor activity of cytotoxic T cells recruited by blinatumomab," commented ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ... class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer ...
Nventa Develops Proprietary Vaccine Adjuvant
... a disease-specific antigen can induce both cytotoxic (T-cell) and antibody (B-cell) immune responses against that antigen. cytotoxic T-cells, also referred to as CD8 T-cells, are ... vaccines; Poly-ICR's ability to induce both cytotoxic and antibody immune responses; our expectation ...... can be delivered subcutaneously, and show that cytotoxic T cell activity is not impaired by long-term BiTE ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ... class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful ...
... of a physician qualified in the use of cytotoxic anti-cancer therapy. Malignant pleural ... is given in combination with other cytotoxic agents; most of these patients had pre-existing ... (Usually when given in combination with other cytotoxic agents and with pre-existing cardiovascular ...
... convenience." About temozolomide TEMODAL (temozolomide), a cytotoxic agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. cytotoxic agents are designed to impact the replication of cells that divide ...
... autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-EpCAM antibody adecatumumab (MT201) against KRAS-mutated ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ...
Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... a new class of therapeutic antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in ...... The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer ... from unresectable malignant mesothelioma. "The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's ...
... greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 ... do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent which should not be given to healthy volunteers, this evaluation is ...
... second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...
CuraGen Updates CR011-vcMMAE Data at ASCO
... mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the ...... (3) Natale, R. et al. Vandetanib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). ABS 31610. ASCO. 2009. (4) Ferlay, J. et al. GLOBOCAN 2002: Cancer Incidence, ...
... Presenter: Elena G. Chiorean, MD Location: Level 2 - West Hall C. Poster Session Track: #79 Developmental Therapeutics: cytotoxic Chemotherapy; Poster Board B19 (Abstract # 2558) About SF1126 SF1126 is the only clinical stage vascular targeted ...
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
... that AR-12 is active in a wide range of tumor types and it also shows promising activity in combination with several widely used approved cytotoxic as well as molecularly targeted anti-cancer agents," stated Dr. Roger G. Berlin, Chief Executive Officer of Arno. About AR-12 AR-12 is a ...... cell lung cancers (SCLC). In in vitro preclinical studies, a fully human, non-fucosylated anti-fucosyl-GM1 antibody, MDX-1110, demonstrated robust cytotoxic effector function (both antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity) for killing tumor cells. Additionally, ...
... EP-100 was fast-acting, destroying LHRH receptor over-expressing OVCAR-3 cells within an hour compared to the unconjugated CLIP 71 which was less cytotoxic and was slow-acting (p<0.005). LHRH receptor negative SKOV-3 cells were significantly less sensitive to EP-100 than OVCAR-3 cells and the effects ...
Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin
... second-generation DNA minor groove binder, has shown potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
... inhibit their repair during the treatment period. Thus siDNA increases the effectiveness of radiotherapy and chemotherapy without adding any cytotoxic effect. The company possesses a portfolio of exclusive worldwide licenses resulting from the pioneering work of its founding scientists at the ...... the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other ...
... been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), ...
Sosei Confirms the Safety of SD118 in Two Phase I Trials
... compression. Also, it is a common secondary symptom in diseases like diabetes, cancer and herpes zoster infection, and can occur after the use of cytotoxic drugs. The condition has a poor prognosis and is a significant cause of morbidity. The neuropathic pain market is forecast to reach US$5.5 billion by ...Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
... melanoma. Patients may have been previously treated with surgery, adjuvant therapy, and/or biotherapy, but cannot have been previously treated with cytotoxic chemotherapy. The patients will be randomized on a 2:1 basis: approximately 250 patients will be treated with Allovectin-7(R) and approximately 125 ...... The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies. The Principle Investigator of the trial is Dr. Charles Shapiro, Director of Breast Oncology at Ohio State University. The trial ...
... mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the ...
... trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in ...
... multi-center, open label, stratified study of RAD001 in 160 patients with advanced pancreatic NET, who became resistant to prior treatment with cytotoxic chemotherapy. In the monotherapy treatment group, 115 patients received RAD001 alone. In the combination treatment group, 45 patients whose tumors ...
Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S.(TM) construct represents a chimeric peptide with bi-functional behavior. ...Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
... the exclusivity of the surface expression of HAAH to cancer cells, suggests the potential clinical utility of PAN-622 for the specific delivery of cytotoxic agents to cancer cells. About Panacea Pharmaceuticals, Inc. Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused ...... properties of corticosteroid medications such as prednisone and methylprednisolone often improve symptoms within days. Immune-suppressing and cytotoxic drugs are used when vasculitis is severe and does not respond to corticosteroids. Thanks to drug treatments, some types of vasculitis that were ...
... synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor ...
... with CUP pose a therapeutic dilemma and treatment is often empiric with a "trial and error" approach. In the era of rapidly growing effective cytotoxic and targeted therapies for known cancers, quicker and more accurate methods of identifying the tissue of origin of CUP cases would permit the use of ...
Other ContentsatresiaspruetropicaltropicaltropicaltropicaltropicaltropicallevellevellevellevellevellevellevellevellevelleveltriglyceridetriglyceridetriglyceridetriglyceridearteriosustrypanosomiasisOther TagsEmbolism
(Date:11/25/2009)...ent State University assistant professors recently...tion (NSF) to continue research beneficial to unde...$890,000. , Christopher Blackwood, assistant pro...as awarded grants to support two separate research...ng Litter Decomposer Communities and Functions fro...
(Date:11/24/2009)...t science is opening new doors to understanding ho...he hearing of a marine mammal or if they hear it ...d X-ray scanners that NASA uses to detect flaws in...s now allowing scientists to peek inside the giant... three-dimensional replicas of a whale,s hearing a...
(Date:11/24/2009)...ger and the American College of Medical Toxicology... the publication of the Journal of Medical Toxico...inning in March 2010. It was previously published... Journal of Medical Toxicology , an international... the science and practice of medical toxicology. ...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2 24750 000 Awarded for Cutting Edge Asthma Research to See Changes in the Lungs During an Attack 56581 1 24750 000 Awarded for Cutting Edge Asthma Research to See Changes in the Lungs During an Attack 56581 2Nuvilex Inc Finalizes Joint Venture Agreement for the Development of Broad Spectrum All Natural Flu Remedies 56578 1Nuvilex Inc Finalizes Joint Venture Agreement for the Development of Broad Spectrum All Natural Flu Remedies 56578 2Nuvilex Inc Finalizes Joint Venture Agreement for the Development of Broad Spectrum All Natural Flu Remedies 56578 3Keeping Kids Safe Through Education 56575 1Keeping Kids Safe Through Education 56575 2(Date:11/26/2009)... Research Triangle Dental (RTDental),...Carolina, today announced the expansion of its ser... Dentist, Dr. Doug Macmillan. , ...Dental is pleased to announce that Dr. Doug Macmil...completed an additional advanced training seminar....
(Date:11/25/2009)...ASCITY,Mo.,Nov.25/PRNewswire/--TheBartleHallConven...edicalcliniconDec.9-10,whenKansasCityhoststhelates...,, "Thisfreecliniceventhasthepotentialtobethebi...fjustoneandbeheldonweekdaysinsteadofoveraweekend,"...thClinicandpresidentoftheNationalAssociationofFree...
(Date:11/25/2009)...BEACH,Calif.,Nov.25/PRNewswire/--Thanksgivingmeals...sinthegreaterLongBeachareathankstoFaithInAction/Vo...ceatHome(IAH),adivisionofSCANHealthPlan.Formoretha...lunteerstodeliverwarmThanksgivingmealstoseniorsinn...osAngelesandsurroundingcities. ,, "Ourwarmholid...
(Date:11/25/2009)...adPoliticalEndorsements,Business,andPressJoinEffor...USNewswire/--Onceagain,theNationalBipolarFoundatio...orsingtheir"Safe,tilStable"program,whichisnowbeing...olardisorder.Today,theNationalBipolarFoundationrec...iorityMailfromtheLt.GovernorofLouisianaMitchLandri...
(Date:11/25/2009)...s increase blood pressure? This simple question h...rs. New Stress-related gene Modulates High Blood ...d pressure? This simple question has been the foc...search has for the first time established a link b...sure response to stress in mice as well as humans....
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2[0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental [1] Kansas City Prepares for Largest Free Health Clinic[0] SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors[0] First Time-Door is Open for Family Discussion of Bipolar Disorder[1] New stress-related gene modulates high blood pressure in mice and men
EhrlichiosisElectromyographyElectrolysisEjaculationElectronystagmographyEmbolusEmbolismEmesisEmpyemaEncopresisEmptyEmergenciesEndocarditisEndometritis
Other Tagsattempt 2attempt 3attempt 4attempt 5attempt 6attempt 7attempt 8attempt 9attempt 10reserves 2materials 2materials 3materials 4materials 5materials 6materials 7materials 8materials 9materials 10concept 2concept 3concept 4concept 5concept 6proves 2proves 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |